BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1762 related articles for article (PubMed ID: 18591625)

  • 1. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
    Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears.
    Bigoni R; Cuneo A; Milani R; Cavazzini F; Bardi A; Roberti MG; Agostini P; della Porta M; Specchia G; Rigolin GM; Castoldi G
    Haematologica; 2001 Apr; 86(4):375-81. PubMed ID: 11325642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
    Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
    Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of -5/5q- chromosome abnormality in myelodysplastic syndromes by interphase fluorescence in situ hybridization].
    Shen Y; Xue Y; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2001 Oct; 22(10):517-9. PubMed ID: 11769675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.
    Douet-Guilbert N; Herry A; LE Bris MJ; Guéganic N; Bovo C; Morel F; DE Braekeleer M
    Anticancer Res; 2011 Mar; 31(3):1007-10. PubMed ID: 21498729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence in situ hybridization for del(5q) in myelodysplasia/acute myeloid leukemia: comparison of EGR1 vs. CSF1R probes and diagnostic yield over metaphase cytogenetics alone.
    Sun Y; Cook JR
    Leuk Res; 2010 Mar; 34(3):340-3. PubMed ID: 19608274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study.
    Pitchford CW; Hettinga AC; Reichard KK
    Am J Clin Pathol; 2010 Feb; 133(2):260-4. PubMed ID: 20093235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
    Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
    Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Several chromosomes involved in translocations with chromosome 5 shown with fluorescence in situ hybridization in patients with malignant myeloid disorders.
    Bram S; Rödjer S; Swolin B
    Cancer Genet Cytogenet; 2004 Nov; 155(1):74-8. PubMed ID: 15527906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics.
    Beyer V; Castagné C; Mühlematter D; Parlier V; Gmür J; Hess U; Kovacsovics T; Meyer-Monard S; Tichelli A; Tobler A; Jacky E; Schanz U; Bargetzi M; Hagemeijer A; de Witte T; van Melle G; Jotterand M
    Cancer Genet Cytogenet; 2004 Jul; 152(1):29-41. PubMed ID: 15193439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of cytogenetics in myelodysplastic syndromes.
    Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Dambruoso I; Caresana M
    Ann N Y Acad Sci; 2006 Nov; 1089():395-410. PubMed ID: 17261783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.
    Evers C; Beier M; Poelitz A; Hildebrandt B; Servan K; Drechsler M; Germing U; Royer HD; Royer-Pokora B
    Genes Chromosomes Cancer; 2007 Dec; 46(12):1119-28. PubMed ID: 17823930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional and molecular cytogenetic features of myelodysplastic syndrome in China.
    Chen L; Li J; Zhu Y; Qiu H; Pan J; Wang R; Qian S; Xu W; Xue Y
    Exp Oncol; 2007 Dec; 29(4):299-303. PubMed ID: 18199987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cryptic deletion in 5q31.2 provides further evidence for a minimally deleted region in myelodysplastic syndromes.
    MacKinnon RN; Kannourakis G; Wall M; Campbell LJ
    Cancer Genet; 2011 Apr; 204(4):187-94. PubMed ID: 21536236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorescence in situ hybridization analysis of 110 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome-acute myeloid leukemia actually differ?
    Lessard M; Hélias C; Struski S; Perrusson N; Uettwiller F; Mozziconacci MJ; Lafage-Pochitaloff M; Dastugue N; Terré C; Brizard F; Cornillet-Lefebvre P; Mugneret F; Barin C; Herry A; Luquet I; Desangles F; Michaux L; Verellen-Dumoulin C; Perrot C; Van den Akker J; Lespinasse J; Eclache V; Berger R;
    Cancer Genet Cytogenet; 2007 Jul; 176(1):1-21. PubMed ID: 17574959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML.
    Herry A; Douet-Guilbert N; Morel F; Le Bris MJ; De Braekeleer M
    Eur J Haematol; 2007 Jun; 78(6):457-67. PubMed ID: 17391336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conventional and molecular cytogenetic findings of myelodysplastic syndrome patients.
    Yilmaz Z; Sahin FI; Kizilkilic E; Karakus S; Boga C; Ozdogu H
    Clin Exp Med; 2005 Jul; 5(2):55-9. PubMed ID: 16096854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Detection of common chromosome abnormalities in myelodysplastic syndrome with a panel fluorescence in situ hybridization].
    Shen Y; Xue Y; Li J; Pan J; Wu Y; Chen S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):160-3. PubMed ID: 12673589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three rearrangements of chromosome 5 in a patient with myelodysplastic syndrome: an atypical deletion 5q, a complex intrachromosomal rearrangement of chromosome 5, and a paracentric inversion of chromosome 5.
    Douet-Guilbert N; Basinko A; Eveillard JR; Morel F; Le Bris MJ; Guéganic N; Bovo C; Herry A; Berthou C; De Braekeleer M
    Cancer Genet Cytogenet; 2010 Dec; 203(2):303-8. PubMed ID: 21156249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of cytogenetic abnormalities involving chromosomes 5,7 and 8 in myelodysplastic syndromes with fluorescence in situ hybridization and its clinical significance].
    Cai Y; Qin YW; Wang C; Yang J; Yan SK
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):6-10. PubMed ID: 17649717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 89.